Innoxel Gets USFDA Nod for Vadodara Plant

  Published 8 months ago

Innoxel Lifesciences received a USFDA EIR, clearing its Vadodara facility for the commercial supply of liquid and oral injectables.

  • USFDA inspection was completed between April 28 and May 2, 2025, with full compliance confirmed.
  • Facility approved for manufacturing, packaging, and distribution of complex dosage forms like liquid injectables and oral liquids.
  • This milestone boosts Innoxel's global credibility and opens doors to US and EU-regulated pharmaceutical markets.

You might like these

L&T Wins Massive High‑Speed Rail Track Contract

Welspun Aunta, Simaria Project Receives Key NHAI Approval

India Fiscal May 2025: Deficit Narrows, Receipts Rise

Subex Powers Dutch MVNO Billing Upgrade

Texas Fund Manager Antitrust Case and Global News Highlights

SMS Lifesciences Jumps 17%

HDFC Bank Gains on Bonus Plan

News that matters the most ⚡